Skip to main content
Jay L. Patel, MD, MBA Vice President, Clinical Trials and PharmaDx
Professor (Clinical), University of Utah School of Medicine Specialties Education Master’s Degree—Business Administration, University of Utah Medical Degree—University of Arizona Residency—Anatomic and Clinical Pathology, University of Utah Fellowship—Hematopathology, Stanford University Certification/Affiliations American Board of Pathology (Anatomic and Clinical Pathology, Hematology) Research Interests Application of next generation sequencing technologies in hematologic malignancies Recent Publications Li P, Alnoor FNU, Xie W, et al. Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS . Leukemia . 2025;39(1):248-256. Kaur A, Rojek AE, Symes E, et al. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms . Blood Cancer J . 2024;14(1):99. Krah NM, Miotke L, Li P, et al. JAK2 R683S mutation resulting in dual diagnoses of chronic eosinophilic leukemia and myelodysplastic/myeloproliferative overlap syndrome . J Natl Compr Canc Netw . 2023;21(12):1218-1223. Patel JL, Erba HP, Savona MR, et al. Genomic data heterogeneity across molecular diagnostic laboratories: a real-world connect myeloid disease registry perspective on variabilities in genomic assay methodology and reporting . J Mol Diagn . 2023;25(8):611-618. Tomlinson B, de Lima M, Cogle CR, et al. Transplant referral patterns for patients with newly diagnosed higher-risk myelodysplastic syndromes and acute myeloid leukemia at academic and community sites in the Connect® Myeloid Disease Registry: potential barriers to care . Transplant Cell Ther . 2023;29(7):460.e1-460.e9. Shomali W, Colucci P, George TI, et al. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group . Leukemia . 2023;37(5):981-987. Agarwal AM, McMurty V, Clayton AL, et al. Clinical utility of targeted next-generation sequencing panel in routine diagnosis of hereditary hemolytic anemia: a national reference laboratory experience . Eur J Haematol . 2023;110(6):688-695. Suknuntha K, Geyer JT, Patel KP, et al. Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation . Leuk Res . 2023;127:107033. Sande CM, Wu R, Yang G, et al. Rapid and automated semiconductor-based next-generation sequencing for simultaneous detection of somatic DNA and RNA aberrations in myeloid neoplasms . J Mol Diagn . 2023;25(2):87-93. Li P, Brown S, Williams M, et al. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms . Blood . 2022;140(7):716-755. Hu B, Patel JL, Tao R, et al. Near complete response to trametinib treatment in histiocytic sarcoma harboring a somatic KRAS mutation . J Natl Compr Canc Netw . 2022;20(6):618-621. Li P, White T, Xie W, et al. AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome . Leukemia . 2022;36(3):664-674. Osman A, Patel JL. Diagnostic challenge and clinical dilemma: the long reach of clonal hematopoiesis . Clin Chem . 2021;67(8):1062-1070.